The present invention relates to a biomarker for diagnosis of overactive bladder (OAB) disease, and a method for screening a drug using the biomarker. The markers described in the present invention can effectively detect or diagnose the onset of OAB by distinguishing them from normal populations. In particular, OAB-specific protein markers released into urine enable simple and rapid OAB diagnosis in a non-invasive manner. In addition, by selecting an agent that changes, particularly normalizes the expression and activity of the markers selected in the present invention, more effective preventative or therapeutic agents of OAB disease can be screened.

As a system that enables effective delivery of a pharmaceutical active ingredient to a submucosal tissue of the bladder, a transmucosal delivery system including a conjugate of a hydrophobic compound containing the pharmaceutical active ingredient and chondroitin sulfate is provided.

The present invention is related to an inhibitor or antagonist of SHP2 for the treatment and/or prevention of a neoplastic disease.

Methods and devices for diagnosing, monitoring, or determining diabetic nephropathy or an associated disorder in a mammal are described. In particular, methods and devices for diagnosing, monitoring, or determining diabetic nephropathy or an associated disorder using measured concentrations of a combination of three or more analytes in a test sample taken from the mammal are described.

Provided are a method and a kit for quantifying L-FABP or oxidized L-FABP in any sample, a method and a kit for testing for kidney diseases on the basis of the quantifying result of L-FABP or oxidized L-FABP in urine of a subject, and a companion diagnostic drug. This method for quantifying liver type fatty acid binding protein includes a step for promoting an antigen-antibody reaction, and quantifying the liver type fatty acid binding protein under a condition in which the measurement sensitivity of oxidized liver type fatty acid binding protein is higher than that of unoxidized liver type fatty acid binding protein.

Methods of treating, or at least inhibiting the onset of, urate transport failure are provided. The methods can include a step for detecting variations in genes that encode ABCG2 protein. When a subject has an SNP of V12M, R113X, Q126X, Q141K, F208S, G268R, E334X, S441N, L447V, S486N, F506SfsX4, R575X, and/or C608X, it can be concluded that the subject has a factor that is capable of inducing urate transport failure, or a state or disease attributable to that failure. When a subject has an SNP of V12M, it can be concluded that, unlike the other SNPs, there is a possibility that the subject does not possess such a factor because, although this variation itself does not lead to a change in urate transport capability, said variation is related to linkage disequilibrium with other SNPs.

The technology described herein is directed to the diagnosis and treatment of sex hormone disorders and/or deficiencies, such as estrogen and/or testosterone disorders and/or deficiencies.

The current disclosure provides methods for detecting and analyzing K17 expression in a bladder sample obtained from a subject. The current disclosure also pertains to methods and kits for identifying a mammalian subject with bladder cancer by detecting the expression of K17 in a sample. The present methods include both cell-based and cell-free methods for determining the level of keratin 17 in a sample obtained from the bladder of a subject.

Compositions and methods are provided for diagnosis and/or prognosis of acute kidney injury risk following medical procedures in a subject. In some embodiments, the method includes measuring and comparing the level of particular proteins to other proteins. In other embodiments, the method includes measuring proteins levels with clinical variable information and comparing this composite with the composite of other protein levels with clinical variable information.

The present invention provides: a method for assisting the evaluation of renal pathological conditions, said method comprising using, as an index, a combination of renal reabsorption and excretion ratios of D-serine and/or D-asparagine in a subject with the blood D-serine and/or D-asparagine levels; a system for evaluating renal pathological conditions; and a program for evaluating renal pathological conditions. The present invention also provides: a method for monitoring renal pathological conditions; and a method for monitoring an effect of treating a renal disease.